SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

LYEL

Lyell Immunopharma, Inc
NEUTRAL
Impact 5/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for S-3 filing in coming weeks which could enable resale and increase share float; assess whether the clinical milestone met is material relative to trial endpoints. The extended cash runway reduces near-term financing risk, but no clinical data was released, evaluate upcoming trial readouts for value inflection.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.50
T+0 close · Mar 9, 2026 · via day close
Latest settled
−41.61%
T+60 · $14.89
Vs SPY
−53.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $25.50entry
  2. T+1 · 8mo ago +0.51%α +0.69% · $25.63
  3. T+5 · 8mo ago −17.14%α −15.78% · $21.13
  4. T+20 · 7mo ago −14.59%α −11.78% · $21.78
  5. T+60 · 6mo ago −41.61%α −53.59% · $14.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 million, following a clinical milestone in its ronde-cel PiNACLE trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer to lead financial strategy amid this capital raise.

Key Financial Metrics

Deal Value
$50.0M

Key Facts

  • Lyell closed an additional $50 million tranche of a $100 million private placement after achieving a clinical milestone in the ronde-cel PiNACLE trial.
  • Total gross proceeds from the private placement are now $100 million, priced at $25.61 per share.
  • Cash runway is expected to extend into Q2 2027.
  • Smital Shah was appointed Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biopharma finance and strategy experience.
  • The securities were sold in a private placement without registration, with investors receiving Form S-3 resale registration rights.

Financial Impact

$50 million in new capital raised at $25.61/share, doubling prior tranche; total $100 million private placement now complete.

cashdilutionrunway

Risk Factors

  • Dilution from $50 million in new shares issued, though pricing was at a fixed $25.61 (current stock price not disclosed).
  • Forward-looking statements dominate; the clinical milestone is not described in detail, so its materiality is uncertain.
  • Private placement may lead to increased share volatility once resale registration becomes effective.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251756

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026